**Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019**

**New York, NY – September 16, 2019** – Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that new clinical data on cosibelimab (formerly CK-301), a potentially differentiated high affinity anti-PD-L1 antibody with functional Fc domain, will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 - October 1, 2019, in Barcelona, Spain. The poster presentation will provide updated interim results from Checkpoint's ongoing multicenter Phase 1 clinical trial, including safety and efficacy data on additional patients and longer follow-up periods from the expansion cohorts. Checkpoint continues to enroll patients into potential registration-enabling cohorts in order to support one or more marketing application submissions based on this ongoing clinical trial.

"We are excited that our interim clinical data on cosibelimab has been selected for presentation at the ESMO Congress this year. With additional patients and longer follow-up, we believe the safety and efficacy data continue to build a compelling case that cosibelimab can be a significant player in a class of PD-(L)1 inhibitors that have grown into a $20 billion annual market," said James F. Oliviero, President and Chief Executive Officer of Checkpoint Therapeutics. "We look forward to sharing our data with the world-renowned oncologists and researchers attending ESMO and the broader oncology community around the world."

Details of the poster presentation are below:

**Title:** Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti-PD-L1 antibody, in patients (pts) with advanced cancers
**Date/Time:** Saturday, September 28, 2019, 12 - 1 p.m. (local time)
**Location:** Hall 4
**Poster Number:** 469P

Following the presentation, the poster will be available on the Publications page of the Pipeline section of Checkpoint's website, www.checkpointtx.com.

Additional information on the meeting can be found on the ESMO website, www.esmo.org.

**About Cosibelimab**
Cosibelimab (formerly referred to as CK-301) is a high affinity, fully-human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death Ligand-1 (PD-L1) and blocks the PD-L1 interaction with the Programmed Death Receptor-1 (PD-1) and B7.1 receptors. PD-L1 is an immune-inhibitory checkpoint molecule expressed on epithelial and vascular endothelial cells, as well as by a number of immune cells, and is utilized by tumor cells as an immune escape mechanism. Cosibelimab's primary mechanism of action is based on the inhibition of the interaction between PD-L1 and its receptors PD-1 and B7.1, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response. Cosibelimab is potentially differentiated from the currently marketed PD-1 and PD-L1 antibodies with a half-life that supports sustained >99% target tumor occupancy and the additional

benefit of a functional Fc domain capable of inducing antibody-dependent cell-mediated cytotoxicity ("ADCC") for potential enhanced efficacy in certain tumor types.

**About Checkpoint Therapeutics**

Checkpoint Therapeutics, Inc. ("Checkpoint") is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer ("NSCLC"). In addition, Checkpoint is currently evaluating its lead antibody product candidate, cosibelimab, a potentially differentiated anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts intended to support one or more Biologics License Application submissions. Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.checkpointtx.com.

**Forward-Looking Statements**

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our plans to submit one or more BLAs and seek accelerated approvals for cosibelimab, statements regarding the potential differentiation of cosibelimab, statements relating to the half-life and functional Fc domain of cosibelimab translating into potential enhanced efficacy, statements relating to how long we believe our cash will fund our operations, any statements relating to our growth strategy and product development programs, and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

**Company Contacts:**
Jaclyn Jaffe and William Begien
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

**Investor Relations Contact:**
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 775-5956
arr@lifesciadvisors.com

**Media Relations Contact:**
Tony Plohoros
6 Degrees

(908) 940-0135
tplohoros@6degreespr.com